Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093900 | 0.83 | MAPT (0.52) | MGMTPOLBALDH1A1KMT2AHTT | |
| SCHEMBL6187801 | 0.81 | KMT2A (0.51) | MGMTPOLBALDH1A1KMT2AHTT | |
| SCHEMBL6187792 | 0.78 | ALDH1A1 (0.54) | MGMTPOLBALDH1A1KMT2AHTT | |
| SCHEMBL7539477 | 0.77 | SYK (0.49) | MGMTL3MBTL1HTR2AHTR2CHTR2B | |
| SCHEMBL3378265 | 0.76 | MAPT (0.44) | POLBALDH1A1KMT2AHTTGAA | |
| SCHEMBL6754375 | 0.76 | ALDH1A1 (0.53) | POLBALDH1A1KMT2AHTTGAA | |
| SCHEMBL7537239 | 0.76 | POLB (0.54) | MGMTPOLBALDH1A1KMT2AHTT | |
| SCHEMBL30716904 | 0.76 | POLB (0.54) | MGMTPOLBALDH1A1KMT2AHTT | |
| SCHEMBL22009630 | 0.74 | HTT (0.50) | ALDH1A1KMT2AHTTGAAMEN1 | |
| SCHEMBL6794700 | 0.74 | ALDH1A1 (0.56) | POLBALDH1A1KMT2AHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1147485-C | Indoline derivatives useful as 5-HT-2C receptor antagonists | ʷ��˿�������ȳ�ķ����˾ | 2004-04-28 | — | — | CN | disclosed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | disclosed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | disclosed |
| CN-1222152-A | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-07-07 | — | — | CN | disclosed |
| EP-0912556-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | HTR2C, HTR1A, HTR1D | MGMT 1854/4885POLB 4422/4885ALDH1A1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.